Prolevi Bio has developed technology intended to help the 10 to 20% of people who do not respond to current treatments for an underactive thyroid gland.
The company has developed a modified formulation of thyroid hormone releasing tablets, mimicking the natural hormone release cycle. In addition, treatment will be tailored to the needs of each patient using the Prolevi Bio mathematical model.
Globally, 750 million patients, mainly women, have hypothyroidism, or an underactive thyroid. However, as many as 600 million patients treated with current medications are dissatisfied with the treatment, and 150 million patients do not respond to drugs at all. Current treatments are unable to follow the discharge cycle of a healthy thyroid gland.
Prolevi Bio has developed a platform technology that releases hormones according to the body’s circadian rhythm. In addition, the drug will act as a precision drug – each patient will receive an individually adapted treatment for optimal effect – with the help of the company’s mathematical models that take into account the patient’s physiological and physical parameters. This technology can also be used for other applications.
Prolevi Bio is raising money
The company has opened an initial round of financing and aims to raise another €5 million to €6 million ($5.4-6.5 million) to finance a phase 1 study validating company innovation with fast-track market authorization in select EU countries under accelerated regulatory approval of the road.
“Going forward, we will develop increasingly sophisticated mathematical models to get better treatment at the individual level and further strengthen our IP portfolio. We are delighted that as an incubator company, we are receiving support and assistance from experienced SmiLe trainers in terms of capital acquisition and critical operational decisions,” said Sahil Gupta, CEO of Prolevi Bio.
SmiLe Incubator is a life science business incubator based in Medicon Village in Lund, Sweden.